

Iperion Limited

Annual Meeting

26 September 2025

Agenda

- Welcome and Introductions
- Formalities
- Presentation to Shareholders
- Q&A Discussion
- Resolutions
- Appendix: Additional information on Pathoglaze

Formalities

- Attendance of the virtual meeting has been left open for all interested to be able to attend.
- The meeting is recorded.
- To ensure that voting is accounted for correctly, all votes will be required to be submitted electronically. For shareholders who have not voted yet via MUFG, but still wish to do so after the meeting, please forward your completed voting form to john.cilliers@iperion.co.nz by no later than 4pm today.
(contact John if you need a form)

Review of the year ended 31 March 2025

- Decrease in interest income as result of lower bank interest rates and deposit value
- Received a \$250,000 discount on fixed Outsource Plant expense. 2024 includes establishment cost of \$100k.
- Admin expenses lower in 2025 mainly in stock exchange fees and marketing activities.
- Impairment expense is on trademark intangibles. Expected to be reversed once the value of sales support the intangibles valuation.
- There were no changes in the number of shares on issue.

	2025 \$	2024 \$
Interest income	20,382	41,396
Outsource Manufacturing Plant	150,000	500,000
Administrative expenses	317,781	354,372
Impairment expense	8,284	9,283
Net loss	455,683	822,259
Net assets	348,398	804,081
Cash and Term deposits	425,341	866,481

Progress and current activities

- Continued marketing activities and presentations at events mainly in South East Asia.
- Ongoing product trials with potential customers across South East Asia, Europe and the Middle East.
- Pathoglaze® trademark registrations completed in accordance with the Madrid protocol
- Initiatives to conserve cash reserves:
 - Fixed annual fee on Pilot Outsource Facility for current financial year is fully discounted by vendor as facility is being supported by research grants obtained.
 - Directors have agreed have agreed to defer payment on 50% of management and director fees starting from November 2025 until achievement of sufficient sales to achieve positive cashflow.



Pathoglaze is a durable, high potency, anti-microbial product capable of being incorporated into raw materials for other products at the point of manufacture.

For example it can be incorporated in plastics masterbatch powders prior to product moulding or it can be applied to existing products as a thin film coating.



- Good progress being made in development of Pathoglaze infused polymer jute bags used for shipping cocoa and coffee beans.
- These bags reduce losses that result from microbial contamination during shipping and transport.
- Likely 1st sales will be with a multinational chocolate manufacturer.



Questions



Resolution 1

Bruce Dunlop retires by rotation in accordance with the Company's constitution and NZX Listing Rule 2.7.1. . Being eligible, Bruce offers himself for re-election. The Board considers Bruce to be an Independent Director. Accordingly, the shareholders of the Company are requested to consider and, if thought fit, pass the following resolution as an Ordinary Resolution.

Ordinary Resolution: That Bruce Dunlop, who retires in accordance with NZX Listing Rule 2.7.1, and being eligible for re-election, be re-elected as a director of IPR.

Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	406,663,155	505,000	0	79.08%	0
Holders	5	7	0		
Percentage	99.88%	0.12%	0.00%		

Resolution 2

Chang Ku EE retires by rotation in accordance with the Company's constitution and NZX Listing Rule 2.7.1. Being eligible, Chang Ku EE offers himself for re-election. The Board does not consider Mr EE to be an Independent Director. Accordingly, the shareholders of the Company are requested to consider and, if thought fit, pass the following resolution as an Ordinary Resolution.

Ordinary Resolution: That Chang Ku EE, who retires in accordance with NZX Listing Rule 2.7.1, and being eligible for re-election, be re-elected as a director of IPR.

Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	406,663,155	505,000	0	79.08%	0
Holders	5	7	0		
Percentage	99.88%	0.12%	0.00%		

Resolution 3

BDO is automatically reappointed at the annual meeting as the auditor of the Company under section 207T of the Companies Act. This resolution authorises the Board to fix the fees and expenses of the auditor.

Ordinary Resolution: That the Board is authorised to fix BDO Auckland’s fees and expenses as the auditor of IPR.


Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	406,663,155	505,000	0	79.08%	0
Holders	5	7	0		
Percentage	99.88%	0.12%	0.00%		

Thank you



- ✓ **PATHOGLAZE® Hyperion** is a high-potency **zinc-based** antimicrobial additive.
- ✓ Having a **core shell- nanopillar morphological structure**.
- ✓ It can kill, reduce and prevent the growth of harmful microorganism (*e.g.: bacteria, virus, fungi, algae*).
- ✓ Having an antimicrobial activity up to **99.9 % (test method: ISO22196)**.
- ✓ Can be **seamlessly incorporated** in a wide range of end-use products during the manufacturing process without interfering with the actual manufacturing setup.




HYPERION Additive
– greyish powder



Key Features



Area of Application



PLASTICS AND POLYMERS (Food-grade and non food-grade)

List of polymers compatible with PATHOGLAZE:

- i. Commodity thermoplastics (*i.e.*: PE, PS)
- ii. Engineering thermoplastics (*i.e.*: PC, ABS, PC/ABS, PA)
- iii. Thermosets (*i.e.*: epoxy)
- iv. Synthetic rubber (*i.e.*: NBR and EPDM)

PAINTS AND COATINGS



Polymer compound

- ✓ Our **PATHOGLAZE®** additives are compatible with almost all plastics and polymer materials (*i.e.: trial for PP, PC and ABS*).
- ✓ With **0.5%** of PATHOGLAZE loading = **99.9%** of antimicrobial activity (ISO22196)
- ✓ Seamlessly compound in polymer using the existing process
- ✓ Embedded within the polymer compound itself, delivering continuous protection against microbes without affecting gloss or matte surfaces, color, durability, and properties.

In-polymer Food Contact Test according to


- **US FDA 21 CFR 177.1520**

PASS

Migration Test according to Commission Regulation (EU)

- **EU 10/2011 Article 3 of European Regulation 1935/2004***

PASS



PP compound with **0.5%** of
PATHOGLAZE



Potential
PATHOGLAZE
APPLICATION



Housewares:

Cutting boards, wall coverings, appliances,
toilet seats, flooring, mattresses



Commercial:

PVC blinds, car interiors, packaging, signs,
electronics, seating



Fitness:

yoga mats, footwear, duffle bags,
sports equipment



Construction materials:

flooring, vinyl siding, windows, insulation,
piping, roofing membranes



Healthcare:

business supplies, medical devices, seating,
countertops, storage



Antimicrobial Packaging (primary & secondary)

- i. Prevents the growth of bacteria and fungi on the surface.
- ii. Reduces bacteria in the surrounding area, and reduces the spread of infection.
- iii. Prolongs food shelf life.
- iv. Promotes product reusability and recyclability.



- ✓ **Thin film** is a **layer of material** with a thickness ranging from a nanometer to micrometer on the surface of a substrate.
- ✓ Harnessing the potential of zinc, PATHOGLAZE thin film is a **zinc-based thin-film** coating.
- ✓ **PATHOGLAZE® thin film** series is particularly targeted for coating on non-porous surfaces *i.e.*; **glass windows, solar panels, touch-sensitive displays, etc.** where transparency coating is a key consideration.

